# Gonadotropin Releasing Hormone Agonist (GnRHa) Versus Estrogen and Progesterone for Luteal Support in High Responders

> **NCT04797338** · PHASE4 · UNKNOWN · sponsor: **Assaf-Harofeh Medical Center** · enrollment: 100 (estimated)

## Conditions studied

- Pregnancy Early
- Miscarriage
- Ovarian Hyperstimulation Syndrome

## Interventions

- **DRUG:** Synarel, 0.2 Mg/Inh Nasal Spray
- **DRUG:** Estrofem
- **DRUG:** Utrogestan
- **DRUG:** Hydroxyprogesterone Caproate

## Key facts

- **NCT ID:** NCT04797338
- **Lead sponsor:** Assaf-Harofeh Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-12-29
- **Primary completion:** 2021-09-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2021-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04797338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04797338, "Gonadotropin Releasing Hormone Agonist (GnRHa) Versus Estrogen and Progesterone for Luteal Support in High Responders". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04797338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*